公司資料
OmniAb 股價、新聞與催化劑
- 股票代碼:
- OABI
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
4.30 USD (+2.63%)
收盤價
最後更新: 2026年8月20日
380M USD
市值
股價為何變動
As of Aug 20, 2026, OABI closed up 2.63% at $4.30. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
OmniAb is a biotechnology platform company that monetizes antibody discovery technology through partnerships and licensing. It provides tools and engineered animal platforms to discover therapeutic antibodies.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, OmniAb sits in biotech infrastructure and discovery platforms.
商業模式特徵
Revenue depends on partner demand, technology adoption, and the economics of platform licensing rather than direct drug sales.
生技產業定位
OmniAb is an enabling antibody-platform name whose value comes from discovery infrastructure and partnership monetization.
未來催化劑
- OmniAb’s catalysts are partner-program milestones, royalty or milestone revenue, and whether the antibody-discovery platform keeps producing value across partners. The market will care about utilization and downstream optionality more than a single headline.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。